HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results.

Abstract
Monoclonal antibody 17-1A was administered to 25 patients with advanced unresectable carcinoma of the pancreas. Ten patients received 17-1A alone in 400 mg doses delivered intravenously, while 15 patients received 400 mg 17-1A absorbed on to autologous peripheral blood mononuclear cells collected by leukapheresis (usual yield greater than 10(9) cells). No toxicity was observed. Twenty-three patients developed circulating anti-murine immunoglobulin within three weeks of treatment, and 11 patients developed circulating anti-idiotypic immunoglobulin. Four out of 19 clinically evaluable patients (21%) showed objective regressions of tumor. Response did not correlate with the presence or absence of anti-idiotypic antibody and did not correlate with the method of treatment with 17-1A alone or 17-1A and mononuclear cells, at the time of current analysis.
AuthorsW F Sindelar, M M Maher, D Herlyn, H F Sears, Z Steplewski, H Koprowski
JournalHybridoma (Hybridoma) Vol. 5 Suppl 1 Pg. S125-32 (Jul 1986) ISSN: 0272-457X [Print] United States
PMID3744377 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
Topics
  • Antibodies, Monoclonal (administration & dosage, therapeutic use, toxicity)
  • Drug Administration Schedule
  • Humans
  • Immunotherapy
  • Pancreatic Neoplasms (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: